Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma Co N.V (NAMS) Enterprise Value: 2022-2025

Historic Enterprise Value for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to $2.5 billion.

  • NewAmsterdam Pharma Co N.V's Enterprise Value rose 133.33% to $2.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $118.4 million, marking a year-over-year increase of 165.48%. This contributed to the annual value of $1.5 billion for FY2024, which is 106.20% up from last year.
  • According to the latest figures from Q3 2025, NewAmsterdam Pharma Co N.V's Enterprise Value is $2.5 billion, which was up 93.21% from $1.3 billion recorded in Q2 2025.
  • Over the past 5 years, NewAmsterdam Pharma Co N.V's Enterprise Value peaked at $2.5 billion during Q3 2025, and registered a low of $379.0 million during Q4 2022.
  • For the 3-year period, NewAmsterdam Pharma Co N.V's Enterprise Value averaged around $1.2 billion, with its median value being $1.3 billion (2025).
  • As far as peak fluctuations go, NewAmsterdam Pharma Co N.V's Enterprise Value soared by 154.62% in 2024, and later dropped by 11.69% in 2025.
  • Quarterly analysis of 4 years shows NewAmsterdam Pharma Co N.V's Enterprise Value stood at $379.0 million in 2022, then soared by 97.10% to $746.9 million in 2023, then surged by 106.20% to $1.5 billion in 2024, then soared by 133.33% to $2.5 billion in 2025.
  • Its Enterprise Value was $2.5 billion in Q3 2025, compared to $1.3 billion in Q2 2025 and $1.4 billion in Q1 2025.